Cargando…

The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients

Background and objective The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus disease 2019 (COVID-19) infection, with symptoms ranging from mild upper respiratory illness to multisystem organ failure, and even death. Since its discovery in D...

Descripción completa

Detalles Bibliográficos
Autores principales: Rangroo, Rohit, Young, Myles, Davis, Alexander, Pack, Steven, Thakore, Shaival, Schepcoff, Anna, Oyesanmi, Olu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148197/
https://www.ncbi.nlm.nih.gov/pubmed/35664402
http://dx.doi.org/10.7759/cureus.24563
_version_ 1784716992451706880
author Rangroo, Rohit
Young, Myles
Davis, Alexander
Pack, Steven
Thakore, Shaival
Schepcoff, Anna
Oyesanmi, Olu
author_facet Rangroo, Rohit
Young, Myles
Davis, Alexander
Pack, Steven
Thakore, Shaival
Schepcoff, Anna
Oyesanmi, Olu
author_sort Rangroo, Rohit
collection PubMed
description Background and objective The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus disease 2019 (COVID-19) infection, with symptoms ranging from mild upper respiratory illness to multisystem organ failure, and even death. Since its discovery in December 2019, the SARS-CoV-2 virus has led to a global pandemic, rapidly spreading to countries around the world, with millions of reported deaths to date. As researchers around the world continue to analyze and interpret the data gathered regarding the novel virus, it is evident that its co-infection with various bacterial pathogens is associated with a worse overall prognosis. One such bacterial pathogen, Mycoplasma pneumoniae (M. pneumoniae), has been associated with an increase in inpatient mortality, length of hospital stay, and need for mechanical ventilation. The aim of this study was to evaluate the characteristics and outcomes of patients co-infected with SARS-CoV-2 and M. pneumoniae. We sought to determine if this co-infection led to increased incidence of ventilatory support, intensive care unit (ICU) stay, and mortality. Materials and Methods A multi-center retrospective study was conducted involving patients aged 18 years and older. We compared the incidence of in-hospital mortality, ICU stay, and mechanical ventilation support between COVID-19-positive patients with and without M. pneumoniae co-infection. Based on the collected data, a binary logistic regression model was implemented to assess the correlation between mortality and ventilatory support, while linear regression was used to study the length of stay (LOS) independent variable. Results A total of 1,208 patients with a positive SARS-CoV-2 test were identified. Among them, 604 (50%) had an M. pneumoniae co-infection. LOS (95% CI for the coefficient estimate [0.86, 1.05], p<0.001), need for mechanical ventilation (95% CI for the odds ratio [2.60, 6.02], p<0.001), and inpatient mortality (95% CI for the odds ratio [1.43, 2.97], p<0.001) among those co-infected were significantly higher compared to COVID-19 patients without concomitant M. pneumoniae infection. Conclusion COVID-19 with a concomitant M. pneumoniae infection was found to have worse outcomes and overall prognosis when compared to individuals with independent disease states. Based on retrospective data gathered from a large multicenter database, the rates of mortality, ventilatory support, and length of hospital stay were significantly worse in patients with a co-infection of SARS-CoV-2 and M. pneumoniae.
format Online
Article
Text
id pubmed-9148197
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-91481972022-06-02 The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients Rangroo, Rohit Young, Myles Davis, Alexander Pack, Steven Thakore, Shaival Schepcoff, Anna Oyesanmi, Olu Cureus Internal Medicine Background and objective The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus disease 2019 (COVID-19) infection, with symptoms ranging from mild upper respiratory illness to multisystem organ failure, and even death. Since its discovery in December 2019, the SARS-CoV-2 virus has led to a global pandemic, rapidly spreading to countries around the world, with millions of reported deaths to date. As researchers around the world continue to analyze and interpret the data gathered regarding the novel virus, it is evident that its co-infection with various bacterial pathogens is associated with a worse overall prognosis. One such bacterial pathogen, Mycoplasma pneumoniae (M. pneumoniae), has been associated with an increase in inpatient mortality, length of hospital stay, and need for mechanical ventilation. The aim of this study was to evaluate the characteristics and outcomes of patients co-infected with SARS-CoV-2 and M. pneumoniae. We sought to determine if this co-infection led to increased incidence of ventilatory support, intensive care unit (ICU) stay, and mortality. Materials and Methods A multi-center retrospective study was conducted involving patients aged 18 years and older. We compared the incidence of in-hospital mortality, ICU stay, and mechanical ventilation support between COVID-19-positive patients with and without M. pneumoniae co-infection. Based on the collected data, a binary logistic regression model was implemented to assess the correlation between mortality and ventilatory support, while linear regression was used to study the length of stay (LOS) independent variable. Results A total of 1,208 patients with a positive SARS-CoV-2 test were identified. Among them, 604 (50%) had an M. pneumoniae co-infection. LOS (95% CI for the coefficient estimate [0.86, 1.05], p<0.001), need for mechanical ventilation (95% CI for the odds ratio [2.60, 6.02], p<0.001), and inpatient mortality (95% CI for the odds ratio [1.43, 2.97], p<0.001) among those co-infected were significantly higher compared to COVID-19 patients without concomitant M. pneumoniae infection. Conclusion COVID-19 with a concomitant M. pneumoniae infection was found to have worse outcomes and overall prognosis when compared to individuals with independent disease states. Based on retrospective data gathered from a large multicenter database, the rates of mortality, ventilatory support, and length of hospital stay were significantly worse in patients with a co-infection of SARS-CoV-2 and M. pneumoniae. Cureus 2022-04-28 /pmc/articles/PMC9148197/ /pubmed/35664402 http://dx.doi.org/10.7759/cureus.24563 Text en Copyright © 2022, Rangroo et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Rangroo, Rohit
Young, Myles
Davis, Alexander
Pack, Steven
Thakore, Shaival
Schepcoff, Anna
Oyesanmi, Olu
The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients
title The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients
title_full The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients
title_fullStr The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients
title_full_unstemmed The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients
title_short The Severity of the Co-infection of Mycoplasma pneumoniae in COVID-19 Patients
title_sort severity of the co-infection of mycoplasma pneumoniae in covid-19 patients
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148197/
https://www.ncbi.nlm.nih.gov/pubmed/35664402
http://dx.doi.org/10.7759/cureus.24563
work_keys_str_mv AT rangroorohit theseverityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT youngmyles theseverityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT davisalexander theseverityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT packsteven theseverityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT thakoreshaival theseverityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT schepcoffanna theseverityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT oyesanmiolu theseverityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT rangroorohit severityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT youngmyles severityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT davisalexander severityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT packsteven severityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT thakoreshaival severityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT schepcoffanna severityofthecoinfectionofmycoplasmapneumoniaeincovid19patients
AT oyesanmiolu severityofthecoinfectionofmycoplasmapneumoniaeincovid19patients